0001636050-21-000033.txt : 20210324 0001636050-21-000033.hdr.sgml : 20210324 20210324192143 ACCESSION NUMBER: 0001636050-21-000033 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210323 FILED AS OF DATE: 20210324 DATE AS OF CHANGE: 20210324 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cheruvu Pavan CENTRAL INDEX KEY: 0001731741 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37418 FILM NUMBER: 21769594 MAIL ADDRESS: STREET 1: C/O AXOVANT SCIENCES, INC. STREET 2: 11 TIMES SQUARE, 33RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sio Gene Therapies Inc. CENTRAL INDEX KEY: 0001636050 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 853863315 FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 130 WEST 42ND STREET STREET 2: 26TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 877-746-4891 MAIL ADDRESS: STREET 1: 130 WEST 42ND STREET STREET 2: 26TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Axovant Gene Therapies Ltd. DATE OF NAME CHANGE: 20190516 FORMER COMPANY: FORMER CONFORMED NAME: Axovant Sciences Ltd. DATE OF NAME CHANGE: 20150324 FORMER COMPANY: FORMER CONFORMED NAME: Axovant Sciences, Inc. DATE OF NAME CHANGE: 20150324 4 1 wf-form4_161662808813010.xml FORM 4 X0306 4 2021-03-23 0 0001636050 Sio Gene Therapies Inc. SIOX 0001731741 Cheruvu Pavan C/O SIO GENE THERAPIES INC. 130 WEST 42ND STREET, 26TH FLOOR NEW YORK NY 10036 1 1 0 0 Chief Executive Officer Common Stock 2021-03-23 4 P 0 100000 2.4818 A 180426 D The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.46 to $2.50 per share, inclusive. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchase at each separate price within the range set forth in this footnote. /s/ David Nassif, Attorney-In-Fact 2021-03-24